



hunter
IMMUNOLOGY

An Oral Immunotherapy Platform

An Investment Opportunity

Presented by David Radford
CEO and Managing Director

This presentation is being provided for the sole purpose of providing the recipients with background information about Hunter Immunology's business.

This presentation, including the information in this disclaimer does not constitute an offer, invitation or recommendation to subscribe for or purchase any security in HIL and neither the presentation, disclaimer nor anything contained in them forms the basis of any contract or commitment.

No representation express or implied is made to the fairness, accuracy, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in the presentation ("forward looking statements"). Such forward looking statements are by their nature subject to significant uncertainties and contingencies and are based upon a number of estimates and assumptions that are subject to change (and in many cases outside the control of HIL and its directors) which may cause the actual results of HIL to be materially different from any future results or performance expressed or implied by such forward looking statements.

To the extent permitted by law, neither HIL nor its related corporations, directors, employees or agents, nor any other person accepts any liability including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it.

You represent and confirm that by attending and/or retaining this presentation, that you accept the above conditions.

1. Hunter is focused on commercialising a breakthrough product, HI-164OV to alleviate a serious, irreversible respiratory disease – Chronic Obstructive Pulmonary Disease (COPD)
2. Hunter's key treatment, HI-164OV significantly reduced the severity of exacerbations in moderate to severe COPD in a Phase IIa trial.
3. Hunter has completed the dosing of **320 patients** in 21 centres in a current fully blinded Phase IIb trial, with results expected in calendar Q2 2012
4. Initial safety data confirms the patient tolerance of the therapy
5. ASX listing through Probiomics (ASX:PCC) on track for Q1 2012.
6. Portfolio expansion on track and in parallel with listing event
7. Several pharma companies showing interest in HI-164OV

Prevalence Table (COPD)

Country	Study	Diagnostic Approach	Age, yr	COPD Prevalence (%)
				Overall
Spain	Pena et al*	Spirometry	40-69	9.1
World	Halbert et al**	Spirometry	≥ 40	9 to 10
		Patient-reported diagnosis		3.7
		Physician diagnosis		4.1
World (Stage II or higher)	Buist et al 2007	Spirometry (GOLD)	≥ 40	10.1
New Zealand	Shirtcliffe et al 2007	Spirometry	≥ 40	14.2
Mexico (Mexico City)	Menezes et al 2005	Spirometry	≥ 40	7.8
	(PLATINO study - funded by Boeringher Engelheim)			
Brazil (Sau Paulo)	Menezes et al 2005	Spirometry	≥ 40	15.8
	(PLATINO study - funded by Boeringher Engelheim)			
Chile (Santiago)	Menezes et al 2005	Spirometry	≥ 40	16.9
	(PLATINO study - funded by Boeringher Engelheim)			
Uruguay (Montevideo)	Menezes et al 2005	Spirometry	≥ 40	19.7
	(PLATINO study - funded by Boeringher Engelheim)			
Venezuela (Caracas)	Gunen et al 2008	Spirometry	≥ 40	12.1
Turkey	Gunen et al 2008	Spirometry and questionnaire	≥ 40	18.1
Japan	Fukuchi et al 2004	Spirometry	≥ 40	10.9

- An average of >10% of the population >40 has some form of COPD
- Approximately 10% of this patient group has Moderate to Severe COPD


- A growing disease amongst >40y.o population (7%+per annum)
 - New indications include exposure to airborne pollutants
 - 25% of new patients have never smoked
- Approximately 10m patients globally with Moderate to Severe COPD
- Compelling economic justification in prevention of hospitalisation
- **Conservative market potential of AUD1b/annum**

Haemophilus influenzae demonstrated to be a major causative agent in infection related exacerbations.
HI-1640V is an enteric-coated tablet containing killed *H.influenzae* bacteria



Stimulates immune response in the gut


Immune cells migrate to airways and provide protection against *H.influenzae*



Aim is to reduce infections and inflammation that cause exacerbations

- 320 Patients
- Multi-site (21 hospitals around Australia)
- Stringent Protocol
- Patient Criteria
 - At least one exacerbation requiring hospitalisation in the last year
- Study is fully recruited
- Safety data from first 100 patients is very positive
- Results expected in April 2012

Patent	Description	Filing Date	Jurisdiction
PT004	Asthma Treatment	March 2008	Major International countries
PT006	ETxB Carrier Protein	June 2002	USA/WIPO
PT011	HI 164 Isolate	Sept 2009	Major International countries
PT001	Isolate Selection	August 2005	Major International Countries
PT007	Probiotic Complement	May 2001	Major International Countries



Contact Details

David Radford

Chief Executive Officer & Managing Director

Mobile +61 (0)407 218 922

Email

david.radford@hunterimmunology.com.au